Pharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: Preclinical study in mice and rats

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Gao, Yan ^a,b   Shen, Jacson K ^a   Choy, Edwin ^a   Zhang, Zhan ^c   Mankin, Henry J ^a   Hornicek, Francis J ^a   Duan, Zhenfeng ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c Medical College of Shangqiu   (China)

Author keywords

[No Author keywords available]

Indexed keywords

(2-(4-METHOXYPHENYL)-4-QUINOLINYL)(2-PIPERIDINYL)METHANOL; ANTINEOPLASTIC AGENT; CYTOCHROME P450; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PIPERIDINE DERIVATIVE; QUINOLINE DERIVATIVE;

ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BLOOD; HUMAN; IC50; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ISOMERISM; MALE; MAXIMUM TOLERATED DOSE; METABOLISM; MOUSE; PRECLINICAL STUDY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE, SUB-FAMILY B, MEMBER 1; CYTOCHROME P-450 ENZYME SYSTEM; DOXORUBICIN; DRUG EVALUATION, PRECLINICAL; HUMANS; INHIBITORY CONCENTRATION 50; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; ISOMERISM; MALE; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED BALB C; PACLITAXEL; PIPERIDINES; QUINOLINES; RATS, SPRAGUE-DAWLEY;

EID: 84971315359     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep25659     Document Type: Article

References (37)

1. Mellor, H. R. and Callaghan, R. Resistance to chemotherapy in cancer: a complex and integrated cellular response. Pharmacology 81, 275-300 (2008).
2. Kartner, N., Riordan, J. R. and Ling, V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221, 1285-1288 (1983).
3. Szakacs, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C. and Gottesman, M. M. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5, 219-234 (2006).
4. Wang, Z. et al. P-glycoprotein substrate models using support vector machines based on a comprehensive data set. J Chem Inf Model 51, 1447-1456 (2011).
5. Chen, L., Li, Y., Yu, H., Zhang, L. and Hou, T. Computational models for predicting substrates or inhibitors of P-glycoprotein. Drug Discov Today 17, 343-351 (2012).
6. Hegedus, T. et al. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta 1587, 318-325 (2002).
7. Wang, X. K. and Fu, L. W. Interaction of tyrosine kinase inhibitors with the MDR-related ABC transporter proteins. Curr Drug Metab 11, 618-628 (2010).
8. Hirayama, C. et al. Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells. Pharm Res 25, 827-835 (2008).
9. Polli, J. W. et al. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299, 620-628 (2001).
10. Crowley, E., McDevitt, C. A. and Callaghan, R. Generating inhibitors of P-glycoprotein: where to, now? Methods Mol Biol 596, 405-432 (2010).
11. Shukla, S., Ohnuma, S. and Ambudkar, S. V. Improving cancer chemotherapy with modulators of ABC drug transporters. Curr Drug Targets 12, 621-630 (2011).
12. Fojo, T. and Bates, S. Strategies for reversing drug resistance. Oncogene 22, 7512-7523 (2003).
13. Morjani, H. and Madoulet, C. Immunosuppressors as multidrug resistance reversal agents. Methods Mol Biol 596, 433-446 (2010).
14. Kang, M. H. et al. The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel. Clin Cancer Res 7, 1610-1617 (2001).
15. Greenberg, P. L. et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 22, 1078-1086 (2004).
16. Abraham, J. et al. A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin Cancer Res 15, 3574-3582 (2009).
17. Pusztai, L. et al. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 104, 682-691 (2005).
18. Duan, Z., Choy, E. and Hornicek, F. J. NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance. PLoS One 4, e7415 (2009).
19. Duan, Z. et al. Synthesis and evaluation of (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (NSC23925) isomers to reverse multidrug resistance in cancer. J Med Chem 55, 3113-3121 (2012).
20. Yang, X. et al. NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo. Gynecol Oncol 137, 134-142 (2015).
21. Yang, X. et al. Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925. Br J Cancer 110, 2896-2904 (2014).
22. Stamer, U. et al. Concentrations of Tramadol and O-desmethyltramadol Enantiomers in Different CYP2D6 Genotypes. Clin Pharmacol and Ther 82, 41-47 (2007).
23. Lipshultz, S. E., Grenier, M. A. and Colan, S. D. Doxorubicin-induced cardiomyopathy. N Engl J Med 340, 653-654, author reply 655 (1999).
24. Rowinsky, E. K., Eisenhauer, E. A., Chaudhry, V., Arbuck, S. G. and Donehower, R. C. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20, 1-15 (1993).
25. Zhang, Z. et al. Preclinical Pharmacokinetics, Tolerability, and Pharmacodynamics of Metuzumab, a Novel CD147 Human-Mouse Chimeric and Glycoengineered Antibody. Mol Cancer Ther 14, 162-173 (2015).
26. Garimella, T. et al. Plasma pharmacokinetics and tissue distribution of the breast cancer resistance protein (BCRP/ABCG2) inhibitor fumitremorgin C in SCID mice bearing T8 tumors. Cancer Chemother and Pharmacol 55, 101-109 (2005).
27. Zhang, X. et al. Preclinical Pharmacological Evaluation of a Novel Multiple Kinase Inhibitor, ON123300, in Brain Tumor Models. Mol Cancer Ther 13, 1105-1116 (2014).
28. Grover, A. and Benet, L. Z. Effects of drug transporters on volume of distribution. AAPS J 11, 250-261 (2009).
29. Nelson, D. R. Cytochrome P450: Structure, Mechanism, and Biochemistry, Edited by Paul, R. Ortiz de Montellano (University of California, San Francisco). J Am Chem Soc 127, 12147-12148 (2005).
30. Granfors, M. T., Backman, J. T., Neuvonen, M. and Neuvonen, P. J. Ciprofloxacin greatly increases concentrations and cypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin Pharmacol and Ther 76, 598-606 (2004).
31. Bu, H. Z., Magis, L., Knuth, K. and Teitelbaum, P. High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probedosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1. Rapid Commun Mass Spectrom 15, 741-748 (2001).
32. Yang, X. et al. Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis. Int J Cancer 137, 2029-2039 (2015).
33. Fukushima, K. et al. Time-dependent interaction of ritonavir in chronic use: the power balance between inhibition and induction of P-glycoprotein and cytochrome P450 3A. J Pharm Sci 102, 2044-2055 (2013).
34. Ward, K. W. and Azzarano, L. M. Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquino linyl)ethyl]phenyl]-4-acridinecarboxamide) in the mouse, rat, dog, and monkey. J Pharmacol Exp Ther 310, 703-709 (2004).
35. Barbier, A. J. et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective alpha7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies. Clin Ther 37, 311-324 (2015).
36. McLaughlin, J. E. et al. Comparison of the maximum tolerated dose (MTD) dermal response in three strains of mice following repeated exposure to acrylic acid. Food Chem Toxicol 33, 507-513 (1995).
37. Zhang, Q., Zeng, S. X. and Lu, H. Determination of Maximum Tolerated Dose and Toxicity of Inauhzin in Mice. Toxicol Rep 2, 546-554 (2015).